Mochida Pharmaceutical Co., Ltd.(JP:4534)
Â¥3,375.00+20.00 (+0.60%)
JP:4534
Mochida Pharmaceutical Co., Ltd. earnings date
Â¥3,375.00
At close:+20.00 (+0.60%)
Want to see JP:4534 full AI Analyst Report?
Mochida Pharmaceutical Co., Ltd. (4534) Q2 2021 Earnings Report
1 Followers
JP:4534 Q2 2021 EPS Results
- Actual EPS
- JPY 59.12
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- JPY 52.74
JP:4534 Q2 2021 Revenue Results
- Actual Revenue
- JPY 26.65B
- Expected Revenue
- JPY 3.74T
- Beat/Miss
- Missed by -JPY 3.71T
- YoY Revenue Growth
- +9.91%
Earnings Announcement Details
- Quarter
- Q2 2021
- Date
- 11/05/2021
- Time
- TBA
- Conference Call
- Friday, November 5, 2021
JP:4534 Upcoming Earnings
Mochida Pharmaceutical Co., Ltd.'s next earnings date is estimated for February 8, 2027, based on past reporting schedules.
Q2 2021 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2021 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2021 Earnings Call Summary
No earnings call summary is available for this earnings event.
JP:4534 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 08, 2027 | 2026 (Q3) | ―- | 70.12 | ― | ― |
| Nov 09, 2026 | 2026 (Q2) | ―100.24 | 55.36 | 81.07% (+44.88) | |
| Aug 03, 2026 | 2026 (Q1) | ―89.77 | 53.43 | 68.01% (+36.34) | |
| May 15, 2026 | 2025 (Q4) | ―44.05 | 2.25 | 1857.78% (+41.80) | |
| Feb 06, 2026 | 2025 (Q3) | ―70.12 | 78.4 | -10.56% (-8.28) | |
| Nov 04, 2025 | 2025 (Q2) | ―55.36 | 35.86 | 54.38% (+19.50) | |
| Aug 01, 2025 | 2025 (Q1) | ―53.43 | 43.85 | 21.85% (+9.58) | |
| May 12, 2025 | 2024 (Q4) | ―2.25 | 2.9 | -22.41% (-0.65) | |
| Feb 07, 2025 | 2024 (Q3) | ―78.40 | 45.09 | 73.87% (+33.31) | |
| Nov 01, 2024 | 2024 (Q2) | ―35.86 | 32.15 | 11.54% (+3.71) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed

